The International Scientists team led by Vienna Medical University has shown that Pary protein associated with the development of the second type of diabetes can also participate in the development of prostate cancer. Research Results published Molecular Cancer magazine.
It is a transcription factor that regulates metabolism, inflammatory processes and cell growth, which is activated by a peroxissist prospector). For more than 20 years, for example, it has been a target for the treatment of diabetes with the help of drugs from Tiazolidider group, such as Pioglitazone. However, researchers have now discovered that this protein may also affect the growth of tumor cells in the prostate gland.
Scientists analyzed the textures and cell cultures obtained from various patients with prostate cancer. Later, researchers compared samples of patients with changing degrees of Pary expression, and showed that the activation of this protein helped suppress the growth of the tumor.
This effect was obtained using pioglitazone, a drug that reduces the metabolic activity of tumor cells and slows down their reproduction.
An additional analysis of clinical data has shown that there was no recurrence of the disease during data collection in prostate cancer and diabetes patients treated with Pary agonists. This shows the potential protective effect of such drugs against the progression of the tumor.
Prostate cancer continues to be one of the most common and dangerous types of cancer in men. Only in Austria causes cancer from every eighth death. According to researchers, a further study of Pary may become the basis for creating more effective treatment strategies.
Previously named The most common type of cancer in which the Russians died.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.